Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis

Inclusion Criteria: 1. Aged ≥18 years; 2. Neuroimaging confirmed acute CVT; 3. Symptoms onset was within 30 days prior to enrollment; 4. Signed the informed consent form. Exclusion Criteria: 1. Patients with bleeding (including those with bleeding disorders due to coagulation and vascular disorders, active peptic ulcers, suspected intracranial hemorrhage, thrombocytopenic purpura, hemophilia, during menstruation, during surgery, urinary tract bleeding, hemoptysis, premature delivery, miscarriage, women immediately after delivery and during the puerperium with bleeding from the sexual organs, etc.); 2. Recently operated patients 3. Patients with a potential for bleeding (such as those with visceral tumors, diverticulitis of the digestive tract, colitis, subacute bacterial endocarditis, severe hypertension, and severe diabetes, etc.); 4. Those who are currently taking anticoagulant drugs and platelet function inhibitors (such as aspirin) and those who are using antifibrinolytic agents; 5. Those with a pre-medication fibrinogen concentration lower than 100 mg/dl; 6. Patients with severe liver or kidney dysfunction and other conditions such as papillary muscle rupture, ventricular septal perforation, cardiogenic shock, and multiple organ failure. 7. Those who have a history of allergy to this preparation.